The AHA IMPLEMENT-EF initiative launched a pharmacy-led cohort to identify and address medication management gaps in patients with HFpEF and HFmrEF.

Evidence supporting medications that slow the heart rate (HR), notably beta-blockers, is overwhelming in heart failure (HF) with reduced ejection fraction. Underwhelming, however, is clinical trial ...

A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the ...

It's as if hospitals, clinicians, and the healthcare system itself were unprepared for such success as a powerful multiple-drug regimen emerged for hospitalized patients with heart failure with ...

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction (EF) above ...

Cystatin C (CysC) is an independent risk factor for adverse outcomes in patients with HF across the ejection fraction (EF) spectrum.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Semaglutide and tirzepatide significantly reduced hospitalization and mortality risk in HFpEF patients compared to sitagliptin, with reductions of 42% and 58%, respectively. The study utilized ...